Tata Elxsi Share Price: Rs 75 dividend, 102% QoQ profit jump — Why brokerages still cut target?

Tata Elxsi Share Price: Shares of Tata Elxsi Limited are under pressure despite strong earnings and a dividend announcement, as brokerages remain cautious on the stock’s near-term growth outlook due to demand uncertainties and execution challenges.

The stock was trading at Rs 4,432.70 on April 22, 2026, down 4.69 per cent for the day. It has declined about 34.2 per cent from its 52-week high and remains volatile even as the company reported a sharp improvement in profitability for the March quarter.

Tata Elxsi Q4 Results

Add Zee Business as a Preferred Source

Tata Elxsi on Tuesday reported a 28 per cent year-on-year rise in net profit at Rs 220 crore for the January-March quarter of FY26, compared with Rs 172 crore in the same period last year.

Revenue from operations increased 9 per cent to Rs 994 crore from Rs 908 crore a year ago. On a sequential basis, net profit jumped 102 per cent from Rs 109 crore in the December quarter, while revenue rose over 4 per cent from Rs 953 crore.

EBITDA stood at Rs 244.6 crore, up 10 per cent quarter-on-quarter, with a margin of 24.6 per cent. Profit before tax came in at Rs 268 crore, rising 11 per cent sequentially and 21 per cent year-on-year, with a margin of 25.6 per cent.

Tata Elxsi Dividend

In addition, Tata Elxsi announced a dividend of Rs 75 per share for FY26, signalling continued cash return to shareholders. However, the record date and payout timeline have not yet been disclosed.

Tata Elxsi Share Price Target

Despite these positives, brokerage firms have flagged multiple concerns that are weighing on sentiment.

Motilal Oswal has maintained a “Sell” rating on the stock with a target price of Rs 3,350, implying a downside of about 25 per cent from current levels. The brokerage highlighted that the company’s growth outlook has turned more conservative, with management guiding for only high single-digit growth in FY27.

According to the brokerage, revenue growth in the March quarter was muted at 0.9 per cent quarter-on-quarter in constant currency terms, missing expectations. While the media and communication segment showed some strength, the healthcare and life sciences vertical declined sharply, reflecting uneven demand trends.

The brokerage also noted that delays in deal closures and longer decision-making cycles are impacting revenue visibility. Although the company continues to win deals across segments, the conversion of these wins into actual revenue is taking longer than expected.

Another key concern flagged is the nature of the ER&D business model, where contracts are typically short-term and require continuous replenishment. Around 10–15 per cent of revenue tends to run off every quarter, making consistent deal flow and execution critical for sustaining growth.

Motilal Oswal expects revenue growth to remain moderate, building in around 7.3 per cent growth for FY27. Over the medium term, it expects revenue to grow at about 7 per cent CAGR between FY26 and FY28, which is lower than historical levels.

Margin outlook, while stable, is also expected to improve only gradually. Although margins expanded in the March quarter due to utilisation gains and currency benefits, factors such as wage hikes, hiring costs and investments in new technologies like GenAI could limit sharp upside. The brokerage expects margins to normalise gradually, with FY27 margin estimated at around 25 per cent.

Return ratios have also declined, with return on equity falling to 21.3 per cent in FY26 compared to significantly higher levels in previous years, indicating some moderation in capital efficiency.

Similarly, Morgan Stanley has maintained an “Underweight” rating on the stock and cut its target price to Rs 4,200 from Rs 5,350, implying a downside of about 5 per cent from current levels.

What Tata Elxsi Management Said?

Management commentary also indicates that clients remain cautious, especially in terms of committing to large deals and ramp-up timelines. Cost optimisation deals continue to dominate in segments like media and communication, while innovation-led spending remains subdued.

The transportation vertical remains a key growth driver, supported by strong demand from original equipment manufacturers and increasing offshoring. However, other segments, such as healthcare and media, are witnessing a slower and uneven recovery, which is impacting overall growth visibility.

While the company indicated that healthcare may have bottomed out in the March quarter, recovery is expected to be gradual and not uniform across segments.

Another factor weighing on sentiment is the delay between deal wins and revenue realisation. New deals typically take 9–12 months to scale, creating a lag in revenue growth even when order inflow remains healthy.

Brokerages also pointed out that utilisation levels, currently around 73 per cent, provide some buffer for margin improvement. However, as growth picks up and hiring resumes, cost pressures could increase, limiting margin expansion.